Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:58 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 7,592 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bones Clear all
Completed Phase 3 Interventional Results available

Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)

NCT00750737
View directory record Official record
Conditions
Invasive Fungal Infections, Hematologic Malignancies
Interventions
Posaconazole, ABLC
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Nov 3, 2026, 4:58 AM EST
Completed Not applicable Interventional

Cementless Alumina-Alumina Total Hip and Hybrid

NCT00764530
View directory record Official record
Conditions
Rheumatoid Arthritis, Osteoarthritis, Post-traumatic Arthritis, Avascular Necrosis
Interventions
Alumina/Alumina, Standard
Device
Lead sponsor
Encore Medical, L.P.
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
3
States / cities
Newport Beach, California • Charleston, South Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Nov 3, 2026, 4:58 AM EST
Terminated Phase 1 Interventional

Distal Radius Steroid

NCT05655130
View directory record Official record
Conditions
Fractures, Bone, Fractures, Closed, Radius Fracture Distal
Interventions
Dexamethasone, Methylprednisolone, Standard of Care
Drug · Other
Lead sponsor
Indiana Hand to Shoulder Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Nov 3, 2026, 4:58 AM EST
Completed Phase 4 Interventional Results available

Opioid-Free Shoulder Arthroplasty

NCT03540030
View directory record Official record
Conditions
Opioid Use, Shoulder Osteoarthritis, Avascular Necrosis, Rotator Cuff Tear, Arthritis;Inflammatory
Interventions
Gabapentin, Celecoxib, toradol, acetaminophen, regional block, propofol, IV lidocaine, rocuronium, vecuronium, sevoflurane, desflurane
Drug
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
50 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Nov 3, 2026, 4:58 AM EST
Terminated Phase 3 Interventional Results available

Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

NCT03386344
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Escondido, California • Greenbrae, California • Walnut Creek, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Nov 3, 2026, 4:58 AM EST
Terminated Phase 3 Interventional Results available

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs

NCT01209702
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
tocilizumab, Placebo
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
15
States / cities
Huntington Beach, California • Aventura, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Nov 3, 2026, 4:58 AM EST
Recruiting Phase 2 Interventional

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

NCT06517875
View directory record Official record
Conditions
Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Interventions
Momelotinib, Luspatercept
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Ann Arbor, Michigan • New York, New York • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Nov 3, 2026, 4:58 AM EST
Completed No phase listed Observational Results available

Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003

NCT01099267
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Not listed
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
14
States / cities
Scottsdale, Arizona • Stanford, California • Lecanto, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Nov 3, 2026, 4:58 AM EST
Completed Phase 2 Interventional Results available

Respiratory Syncytial Virus - RSV Protocol

NCT01502072
View directory record Official record
Conditions
Bone Marrow Transplant Infection, Infection in Marrow Transplant Recipients, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Pneumonia, Cancer, Acute Leukemia
Interventions
Ribavirin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Nov 3, 2026, 4:58 AM EST
Recruiting No phase listed Observational

Study of Factors Regulating Mast Cell Proliferation

NCT00044122
View directory record Official record
Conditions
Mastocytosis, Monoclonal, Bone Marrow, Tryptase
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 80 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 3, 2026, 4:58 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Centocor Microarray Study of Patients

NCT00462072
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease
Interventions
Infliximab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Nov 3, 2026, 4:58 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation

NCT00609739
View directory record Official record
Conditions
Leukemia
Interventions
cyclosporine, cytarabine, filgrastim, methotrexate, methylprednisolone, mitoxantrone hydrochloride, allogeneic bone marrow transplantation, umbilical cord blood transplantation, Cis-Retinoic acid
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Nov 3, 2026, 4:58 AM EST
Not listed Phase 1Phase 2 Interventional

Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS

NCT02576301
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndromes
Interventions
Phase 1 - OXi4503, Phase 1 - OXi4503 + cytarabine, Phase 2 - OXi4503 + cytarabine
Drug
Lead sponsor
Mateon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Los Angeles, California • Gainesville, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Nov 3, 2026, 4:58 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Building Better Bones in Children

NCT00063037
View directory record Official record
Conditions
Osteoporosis
Interventions
Behavioral modification - nutrition education
Behavioral
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years to 10 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 4:58 AM EST
Completed Not applicable Interventional Results available

Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women

NCT00361595
View directory record Official record
Conditions
Osteoporosis
Interventions
zoledronic acid
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Up to 85 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Nov 3, 2026, 4:58 AM EST
Completed Phase 1 Interventional

Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors

NCT00019630
View directory record Official record
Conditions
Childhood Soft Tissue Sarcoma, Childhood Liver Cancer, Bone Cancer, Brain Tumor, Kidney Tumor
Interventions
doxorubicin HCl liposome
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Timeline
Started 1999
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Nov 3, 2026, 4:58 AM EST
Completed Phase 2 Interventional Results available

An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly

NCT00171730
View directory record Official record
Conditions
Acromegaly
Interventions
Pasireotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Nov 3, 2026, 4:58 AM EST
Recruiting Phase 1 Interventional

Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

NCT02013336
View directory record Official record
Conditions
Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma, Osteosarcoma
Interventions
MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
Drug
Lead sponsor
South Plains Oncology Consortium
Network
Eligibility
12 Months to 20 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
5
States / cities
Cincinnati, Ohio • Oklahoma City, Oklahoma • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 3, 2026, 4:58 AM EST
Completed No phase listed Observational

Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study

NCT00056719
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Nov 3, 2026, 4:58 AM EST
Completed No phase listed Observational

Evaluate Effectiveness of the Biomet Lumbar Spinal Fusion System

NCT00758719
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Not listed
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Terre Haute, Indiana • Flint, Michigan • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Nov 3, 2026, 4:58 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Advanced SPinal Innovations With Robotics and Enabling Technology Registry

NCT05071144
View directory record Official record
Conditions
Spine Deformity, Idiopathic Scoliosis, Adolescent Idiopathic Scoliosis, Spondylolisthesis, Congenital Scoliosis, Neuromuscular Scoliosis
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Years to 21 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Nov 3, 2026, 4:58 AM EST
Terminated No phase listed Observational

MDR - Longevity IT Oblique and Offset Liners

NCT05980234
View directory record Official record
Conditions
Non-inflammatory Degenerative Joint Disease (NIDJD), Avascular Necrosis, Protrusio Acetabuli, Traumatic Arthritis, Slipped Capital Femoral Epiphyses, Fracture of the Pelvis, Diastrophic Variant, Osteoarthritis, Fused Hip
Interventions
Total Hip Arthroplasty with Longevity IT Oblique Liners, Total Hip Arthroplasty with Longevity IT Offset Liners
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Nov 3, 2026, 4:58 AM EST
Completed Phase 2 Interventional

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

NCT00053001
View directory record Official record
Conditions
Anemia, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
epoetin alfa, thalidomide
Biological · Drug
Lead sponsor
Fallon Clinic
Industry
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
2
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Nov 3, 2026, 4:58 AM EST
Completed Not applicable Interventional Results available

Comparison of Operating Room Time Length With the Use of Virtual Surgical Planning Versus Conventional Treatment of Mandible Fractures

NCT04283981
View directory record Official record
Conditions
Mandibular Fractures
Interventions
Control group without use of VSP, Treatment Group with use of VSP
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Nov 3, 2026, 4:58 AM EST